Shilpa Medicare shares rally over 5% after DRDO approves manufacture, sale of anti-Covid drug
Share of Shilpa Medicare rallied over five percent after the company received in-principle approval from the Defence Research & Development Organisation (DRDO) to manufacture and sale of 2-Deoxy-D-Glucose (2DG). The Drug Controller General of India (DCGI) had granted emergency approval to 2DG for COVID-19 patients…
